Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd
Your view on RCE.AX
Overview
What the company does, where it operates, and who runs it.
About Recce Pharmaceuticals Ltd
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James Hamilton-Bray Graham
- Headquarters
- Governor Macquarie Tower, Sydney, NSW, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James Hamilton-Bray Graham
- Headquarters
- Governor Macquarie Tower, Sydney, NSW, AU
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom.
The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants.
Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Recce Pharmaceuticals Ltd. Starting points for Recce Pharmaceuticals Ltd: EPS -AUD 0.05, beta 0.39 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Recce Pharmaceuticals Ltd. Recce Pharmaceuticals Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Recce Pharmaceuticals Ltd. Trailing twelve-month EPS for Recce Pharmaceuticals Ltd stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | −AUD 0.09 | −AUD 0.09 |
| Lowest estimate | −AUD 0.14 | −AUD 0.20 |
| Highest estimate | −AUD 0.04 | AUD 0.02 |
| Number of analysts | 2 | 2 |
| A year ago | −AUD 0.05 | — |
| Growth vs a year ago | −74.1% | — |
Revenue estimates
| Total | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|
| Average estimate | AUD 3.39M | AUD 19.21M |
| Lowest estimate | AUD 2.92M | AUD 18.61M |
| Highest estimate | AUD 3.86M | AUD 19.82M |
| Number of analysts | 2 | 1 |
| A year ago | AUD 0.00 | — |
| Growth vs a year ago | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Recce Pharmaceuticals Ltd. Recce Pharmaceuticals Ltd has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| BIT.AXBiotron Limited | Healthcare | Biotechnology | — | ||
| BOT.AXBotanix Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| ILA.AXIsland Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| IMC.AXImmuron Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PRQRProQR Therapeutics N.V. | Healthcare | NASDAQ | $155.2M | ||
| PRRUFImmutep Limited | Healthcare | OTC | $368.0M | ||
| PRTAProthena Corporation plc | Healthcare | NASDAQ | $428.8M | ||
| PRTCYPureTech Health plc | Healthcare | OTC | — | ||
| PRVCFPreveCeutical Medical Inc. | Healthcare | OTC | $10.1M | ||
| PSYBFPsyBio Therapeutics Corp. | Healthcare | OTC | $1,275 | ||
| PTCHFPureTech Health plc | Healthcare | OTC | $410.4M | ||
| PTCTPTC Therapeutics, Inc. | Healthcare | NASDAQ | $5.0B | ||
| PTGXProtagonist Therapeutics, Inc. | Healthcare | NASDAQ | $8.3B | ||
| PTHSPelthos Therapeutics Inc. | Healthcare | AMEX | $27.9M | ||
| PTIXProtagenic Therapeutics, Inc. | Healthcare | NASDAQ | $470,654 | ||
| PTNPalatin Technologies, Inc. | Healthcare | NASDAQ | $9.2M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Recce Pharmaceuticals Ltd. Coverage tracks Recce Pharmaceuticals Ltd within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Recce Pharmaceuticals Ltd.